1. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry
   Adam D. Durbin et al, 2018, Nature Genetics CrossRef
2. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
   Yan Su et al, 2020, Molecular Oncology CrossRef
3. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma
   Hongjun Fan et al, 2022, Pediatric Hematology and Oncology CrossRef
4. Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging
   Zhiyang Wu et al, 2021, Cancers CrossRef
5. Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth of High-Risk Neuroblastoma Patients
   Khin K.M. Thwin et al, 2020, The Journal of Molecular Diagnostics CrossRef
6. Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel
   Esther M. van Wezel et al, 2019, JCO Precision Oncology CrossRef
7. Very long‐term molecular follow‐up of minimal residual disease in patients with neuroblastoma
   Andrei Tchirkov et al, 2018, Pediatric Blood & Cancer CrossRef
8. Advances in liquid biopsy in neuroblastoma
   Zhenjian Zhuo et al, 2022, Fundamental Research CrossRef
9. Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma
   Yan Su et al, 2019, Cancer Medicine CrossRef
10. Cell surface vimentin‐positive circulating tumor cell‐based relapse prediction in a long‐term longitudinal study of postremission neuroblastoma patients
    Izhar S. Batth et al, 2020, International Journal of Cancer CrossRef
11. Investigation of patient factors associated with the number of transfusions required during chemotherapy for high‐risk neuroblastoma
    Saori Konno et al, 2022, Vox Sanguinis CrossRef